Scientists benefit from an ultra-sensitive technology improving the existing assays by simply exchanging the fluorophor or enzyme labelled antibody by a DNA-antibody conjugate
Chimera Biotec has introduced Imperacer to the diagnostics and analytics market.
The platform technology enables the increase of detection limits for an Elisa by factor 1000 and more, it claims.
Imperacer is said to combine both the benefits of immunology for specific protein binding and of (real-time) PCR for efficient signal amplification for an ultra sensitive read-out.
It is used for human and veterinarian diagnostics, bio-pharmaceutical research, biological defence, food and beverage, cosmetics etc, and finds its applications in ambitious analytics such as HIV and hepatitis B detection, prion analysis, pharmacokinetic, detection of toxins in food and beverage, quality assurance in cosmetics and more.
Wherever you use an Elisa, it will be improved by Imperacer, claims Chimera.
Scientists benefit from an ultra-sensitive technology improving the existing assays by simply exchanging the fluorophor or enzyme labelled antibody by a DNA-antibody conjugate.
Imperacer is said to result in 1000+ fold higher sensitivity compared to fluorescence Elisa detection at steady specificity, wide linearity (over five decades) for best quantification, high reliability because of easy handling protocols, accelerated research projects with less experiments, and enhanced significance in clinical trials.
Imperacer allows for example the detection of as little as 0.01amol (approximately 6000 molecules) antigen in a sample under optimum conditions.
In typical assays, quantifications of 0.1 picogram IgG are possible with standard deviations below 5%.
